Since anthracyclines were introduced in the treatment of non-Hodgkin's lymphoma in the late 1960s, they have been acknowledged as a cornerstone in the management of the disease and, in particular, of aggressive lymphomas. The high efficacy of anthracycline-containing regimens must, however, be balanced against the drug-related toxicity, which mainly affects the cardiovascular system and represents a major concern for clinicians, especially in the treatment of elderly patients. Patients' outcomes could be further improved, particularly for those at high risk of cardiotoxicity, by substituting liposomal doxorubicin for conventional doxorubicin. This approach has already been tested and shown to be effective in several cancers, especially in different subsets of patients with diffuse large B-cell lymphoma. The use of liposomal doxorubicin in combination regimens for other conditions, such as follicular lymphoma and splenic marginal zone lymphoma, is also under investigation, and early results are promising.

Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma / Luminari, Stefano; Montanini, Antonella; Federico, Massimo. - In: HEMATOLOGY REPORTS. - ISSN 2038-8322. - ELETTRONICO. - 3:3(2011), pp. 10-13. [10.4081/hr.2011.s3.e4]

Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma.

LUMINARI, Stefano;MONTANINI, Antonella;FEDERICO, Massimo
2011

Abstract

Since anthracyclines were introduced in the treatment of non-Hodgkin's lymphoma in the late 1960s, they have been acknowledged as a cornerstone in the management of the disease and, in particular, of aggressive lymphomas. The high efficacy of anthracycline-containing regimens must, however, be balanced against the drug-related toxicity, which mainly affects the cardiovascular system and represents a major concern for clinicians, especially in the treatment of elderly patients. Patients' outcomes could be further improved, particularly for those at high risk of cardiotoxicity, by substituting liposomal doxorubicin for conventional doxorubicin. This approach has already been tested and shown to be effective in several cancers, especially in different subsets of patients with diffuse large B-cell lymphoma. The use of liposomal doxorubicin in combination regimens for other conditions, such as follicular lymphoma and splenic marginal zone lymphoma, is also under investigation, and early results are promising.
2011
3
3
10
13
Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma / Luminari, Stefano; Montanini, Antonella; Federico, Massimo. - In: HEMATOLOGY REPORTS. - ISSN 2038-8322. - ELETTRONICO. - 3:3(2011), pp. 10-13. [10.4081/hr.2011.s3.e4]
Luminari, Stefano; Montanini, Antonella; Federico, Massimo
File in questo prodotto:
File Dimensione Formato  
hr-2011-s3-e4.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 571.64 kB
Formato Adobe PDF
571.64 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/737457
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 17
  • ???jsp.display-item.citation.isi??? ND
social impact